KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer
Mcarthur H, Cortes J, Dent R, Pusztai L, Kuemmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Zhu Y, Pan W, Tryfonidis K, Karantza V, O'Shaughnessy J, Schmid P (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: SPRINGER
City/Town: NEW YORK
Pages Range: 338-338
Conference Proceedings Title: ANNALS OF SURGICAL ONCOLOGY
Authors with CRIS profile
Involved external institutions
University of Texas Southwestern Medical Center (UT Southwestern)
United States (USA) (US)
Vall d'Hebron Institute of Oncology: VHIO
Spain (ES)
National University of Singapore (NUS)
Singapore (SG)
Yale University
United States (USA) (US)
Charité - Universitätsmedizin Berlin
Germany (DE)
Karolinska University Hospital / Karolinska Universitetssjukhuset
Sweden (SE)
Philipps-Universität Marburg
Germany (DE)
Sungkyunkwan University (SKKU)
Korea, Republic of (KR)
Westmead Hospital
Australia (AU)
Klinikum der Universität München
Germany (DE)
HELIOS Kliniken
Germany (DE)
Champalimaud Foundation / Fundação Champalimaud
Portugal (PT)
The US Oncology Network
United States (USA) (US)
University of Ulsan / 울산대학교
Korea, Republic of (KR)
Hôpital général juif - Jewish General Hospital
Canada (CA)
Queen Mary, University of London
United Kingdom (GB)
United States (USA) (US)
Vall d'Hebron Institute of Oncology: VHIO
Spain (ES)
National University of Singapore (NUS)
Singapore (SG)
Yale University
United States (USA) (US)
Charité - Universitätsmedizin Berlin
Germany (DE)
Karolinska University Hospital / Karolinska Universitetssjukhuset
Sweden (SE)
Philipps-Universität Marburg
Germany (DE)
Sungkyunkwan University (SKKU)
Korea, Republic of (KR)
Westmead Hospital
Australia (AU)
Klinikum der Universität München
Germany (DE)
HELIOS Kliniken
Germany (DE)
Champalimaud Foundation / Fundação Champalimaud
Portugal (PT)
The US Oncology Network
United States (USA) (US)
University of Ulsan / 울산대학교
Korea, Republic of (KR)
Hôpital général juif - Jewish General Hospital
Canada (CA)
Queen Mary, University of London
United Kingdom (GB)
How to cite
APA:
Mcarthur, H., Cortes, J., Dent, R., Pusztai, L., Kuemmel, S., Bergh, J.,... Schmid, P. (2022). KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer. In ANNALS OF SURGICAL ONCOLOGY (pp. 338-338). NEW YORK: SPRINGER.
MLA:
Mcarthur, Heather, et al. "KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer." Proceedings of the ANNALS OF SURGICAL ONCOLOGY NEW YORK: SPRINGER, 2022. 338-338.
BibTeX: Download